Report : Europe Exosome Diagnostic and Therapeutic Market Forecast to 2027 - COVID-19 Impact and Regional Analysis By Application (Diagnostic and Therapeutic); Product (Instruments, Reagents, and Software); End User (Cancer Institute, Hospitals, Diagnostic Centers, and Other End Users), and Country
Diagnostic Application Segment to Grow at Faster Pace During Forecast Period
According to a new market research study of "Europe Exosome Diagnostic and Therapeutic Market 2027 – Regional Analysis and Forecast by Application, Product, and End User," the Europe exosome diagnostic and therapeutic market is projected to reach US$1,04,694.72 thousand by2027 from US$ 12,524.24 thousand in 2019. The market is estimated to grow at CAGR of 32.5% from 2020 to 2027. The report highlights trends prevailing in the Europe exosome diagnostic and therapeutic market and the factors driving market along with those that act as hindrances.
The Europe exosome diagnostic and therapeutic market, based on application, is further segmented into diagnostic and therapeutic. The diagnostic segment held a larger share of the market in 2019. Also, the diagnostic segment is estimated to register a higher CAGR during the forecast period owing to increasing adoption to exosomes for the diagnosis of chronic conditions and increasing awareness of procedural outcomes served by exosomes. Increasing awareness about exosomes diagnostics is propelling the companies to enter into this market to tap lucrative opportunities. For instance, the rising cancer population in the country is driving demand of exosome based diagnostic therapies. Moreover, as per the Globocan, in 2018, around 409,808 new cases of cancer were recorded. Breast cancer is one of the highest occurring cancers among women, accounting for 30.1% of total cancer cases.
The Europe exosome diagnostic and therapeutic market is expected to grow owing to factors such as greater precision and advantages over traditional methods of diagnosis and therapeutics and increasing number of research activities in the field of exosomes. However, poor infrastructure and lack of expertise required for isolation of exosomes are likely to restrain the growth of the market during the forecast period.
Leading companies operating in the exosome diagnostic and therapeutic market are Aethlon Medical, Inc., ReNeuron Group plc, Immune Therapy Holdings AB, Cell Guidance Systems LLC, BioRegenerative Sciences, Evomic Science LLC, NorgenBiotek Corp., Exosome Diagnostics, Inc. Bio-Techne, and MiltenyiBiotec, among others.
The report segments Europe exosome diagnostic and therapeutic market as follows:
By End User
- Cancer Institutes
- Diagnostic Centers